Akoya Biosciences, Inc. and Team SAMBAI announced on April 2, 2025, that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. Team SAMBAI is funded through the Cancer Grand Challenges initiative, receiving up to $25 million for the project.
The initiative, named 'Societal, Ancestry, Molecular and Biological Analyses of Inequalities' (SAMBAI), aims to understand the mechanisms and contributions of genetics, biology, environmental, and social determinants to cancer risk and outcomes in diverse populations. The study will assess disparate cancer outcomes in 40,000 individuals of African descent from Africa, the UK, and the US.
Teams from Johns Hopkins University, Nottingham University, Glasgow University, and King’s College London will utilize the PhenoCycler-Fusion system to process thousands of patient samples. This large-scale adoption validates the high-plex and high-throughput capabilities of Akoya's platform for significant research initiatives, focusing on breast, pancreatic, and prostate cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.